TC
CHRS icon

TFS Capital’s Coherus Oncology CHRS Stock Holding History

TFS Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-52,513
Closed -$1.48M – 683
2016
Q4 		$1.48M Buy
52,513
+43,480
+481% +$1.22M 0.4% 50
2016
Q3 		$242K Buy
+9,033
New +$246K 0.06% 481
2016
Q2 		– Sell
-13,167
Closed -$280K – 988
2016
Q1 		$280K Buy
+13,167
New +$216K 0.04% 671

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TFS Capital's CHRS Position: Q1 2017 in Review

TFS Capital sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 52,513 shares — an estimated $1.48M sold.

TFS Capital first reported a position in CHRS in Q1 2016 and held it in 3 quarters. The position peaked at $1.48M in Q4 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

  • TFS Capital reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 52,513 Coherus Oncology shares in Q1 2017, an estimated $1.48M.
  • TFS Capital first reported a position in Coherus Oncology in Q1 2016 and held it in 3 quarters.
  • TFS Capital's Coherus Oncology position peaked at $1.48M in Q4 2016.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.